ONCY Oncolytics Biotech Inc.
USHealthcareAs of 2026-07-10 16:00
Why ONCY matters now
Oncolytics Biotech Inc. (ONCY) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.89 with -3.55% on the session and $89.1M in market capitalization; recent performance reads 1-month +23.87% and YTD +9.84%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-12.9M, and EPS of $-0.11. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -22.6%.
The latest indexable market news headline is "Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Glover Stephen C. filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-29.76
P/S
0.00
EV/EBITDA
-3.64
DCF Value
$0.02
FCF Yield
-22.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
5214.4%
ROA
-435.3%
ROIC
-1221.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-12.9M | $-0.11 |
| Q4 2025 | $0.00 | $-2.1M | $-0.02 |
| FY 2025 | $0.00 | $-39.5M | $-0.41 |
| Q3 2025 | $0.00 | $-14.4M | $-0.14 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
1.08
Oncolytics Biotech Inc. is a biopharmaceutical firm in its development phase, concentrating its efforts on discovering and creating novel pharmaceutical agents to combat cancer. Its primary therapeutic candidate is pelareorep, an immunotherapeutic drug delivered intravenously, designed to target and treat both solid tumors and various blood-related cancers. The company has established strategic co-development agreements with major pharmaceutical companies, Merck KGaA and Pfizer Inc., as well as with PrECOG LLC. These collaborations are focused on advancing pelareorep for use in conjunction with paclitaxel and avelumab (a human anti-PD-L1 antibody). This specific combination therapy is being developed to address hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer. Oncolytics Biotech Inc. was founded in 1998 and is based in Calgary, Canada.